VKTX Viking Therapeutics Stock Outlook 2026: VK2735 Obesity Drug vs LLY NVO
VKTX Viking Therapeutics 2026. VK2735 obesity Phase 3, oral GLP-1 race vs LLY NVO, VK0214 X-ALD pipeline, M&A optionality and clinical scenarios.
VKTX Viking Therapeutics biotech